Role of PFKFB3-Driven Glycolysis in Vessel Sprouting  by De Bock, Katrien et al.
Role of PFKFB3-Driven
Glycolysis in Vessel Sprouting
Katrien De Bock,1,10,20 Maria Georgiadou,1,10,20 Sandra Schoors,1,10 Anna Kuchnio,1,10 Brian W. Wong,1,10
Anna Rita Cantelmo,1,10 Annelies Quaegebeur,1,10 Bart Ghesquie`re,1,10 Sandra Cauwenberghs,1,10 Guy Eelen,1,10
Li-Kun Phng,2,11 Inge Betz,1,10 Bieke Tembuyser,1,10 Katleen Brepoels,1,10 Jonathan Welti,1,10 Ilse Geudens,2,11
Inmaculada Segura,1,10 Bert Cruys,1,10 Franscesco Bifari,1,10 Ilaria Decimo,1,10 Raquel Blanco,14 Sabine Wyns,1,10
Jeroen Vangindertael,3 Susana Rocha,3 Russel T. Collins,14 Sebastian Munck,4,12 Dirk Daelemans,5 Hiromi Imamura,15
Roland Devlieger,6 Mark Rider,16 Paul P. Van Veldhoven,7 Frans Schuit,8 Ramon Bartrons,17 Johan Hofkens,3
Peter Fraisl,1,9,10,13 Sucheta Telang,18 Ralph J. DeBerardinis,19 Luc Schoonjans,1,10 Stefan Vinckier,1,10 Jason Chesney,18
Holger Gerhardt,2,11,14 Mieke Dewerchin,1,10 and Peter Carmeliet1,10,*
1Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, Department of Oncology
2Vascular Patterning Laboratory, Vesalius Research Center, Department of Oncology
3Molecular Imaging and Photonics Laboratory
4Center for Human Genetics
5Laboratory of Virology and Chemotherapy, Rega Institute
6Department of Gynaecology and Obstetrics
7Laboratory of Lipid Biochemistry and Protein Interactions
8Gene Expression Unit
9Laboratory of Cell Proliferation, Vesalius Research Center, Department of Oncology
University of Leuven, Leuven 3000, Belgium
10Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center
11Vascular Patterning Laboratory, Vesalius Research Center
12Center for the Biology of Disease
13Laboratory of Cell Proliferation, Vesalius Research Center
VIB, Leuven 3000, Belgium
14Vascular Biology Laboratory, London Research Institute, Cancer Research UK, London WC2A 3LY, UK
15The Hakubi Center for Advanced Research and Graduate School of Biostudies, Kyoto University, Kyoto 606-8501, Japan
16Hormone and Protein Phosphorylation Research Laboratory, De Duve Institute, Universite´ de Louvain, Brussels 1200, Belgium
17Departament de Cie`ncies Fisiolo`giques II, Universitat de Barcelona, IDIBELL, Barcelona 08907, Spain
18James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA
19Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390-8502, USA
20These authors contributed equally to this work
*Correspondence: peter.carmeliet@vib-kuleuven.be
http://dx.doi.org/10.1016/j.cell.2013.06.037SUMMARY
Vessel sprouting by migrating tip and proliferating
stalk endothelial cells (ECs) is controlled by genetic
signals (such as Notch), but it is unknown whether
metabolism also regulates this process. Here, we
show that ECs relied on glycolysis rather than on
oxidative phosphorylation for ATP production and
that loss of the glycolytic activator PFKFB3 in ECs
impaired vessel formation. Mechanistically, PFKFB3
not only regulated EC proliferation but also
controlled the formation of filopodia/lamellipodia
and directional migration, in part by compartmen-
talizing with F-actin in motile protrusions. Mosaic
in vitro and in vivo sprouting assays further re-
vealed that PFKFB3 overexpression overruled the
pro-stalk activity of Notch, whereas PFKFB3 defi-
ciency impaired tip cell formation upon Notchblockade, implying that glycolysis regulates vessel
branching.
INTRODUCTION
Vessel sprouting relies on the induction of endothelial cells (ECs)
into specialized subtypes, each performing specific functions.
Tip cells at the forefront of the vascular branch extend long filo-
podia and navigate but rarely proliferate, whereas trailing stalk
cells proliferate to elongate the branch (Geudens and Gerhardt,
2011; Potente et al., 2011). Once the vessel is perfused, ECs
become quiescent phalanx cells. Several genetic factors coordi-
nate tip, stalk, and phalanx cell phenotypes (Geudens and Ger-
hardt, 2011; Potente et al., 2011). For instance, Notch signaling
potently controls vessel branching by stimulating the stalk cell
phenotype (Potente et al., 2011). Hence, blockade of Notch
signaling induces vascular hypersprouting, while activation of
the Notch pathway causes the opposite effect. However, a role
for metabolism in vessel sprouting has not been studied to date.Cell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc. 651
Only a limited number of reports have characterized the meta-
bolic pathways in ECs in vitro, and even fewer reports have stud-
ied how EC metabolism regulates angiogenesis in vivo (Dobrina
and Rossi, 1983; Harjes et al., 2012; Laing et al., 1992; Mertens
et al., 1990; Peters et al., 2009). Despite immediate access to
oxygen in the blood, ECs have been reported to rely on glycolysis
(Dobrina and Rossi, 1983; Kru¨tzfeldt et al., 1990; Mertens et al.,
1990). However, other studies have claimed that glutamine and
fatty acids weremore essential substrates, suggesting an impor-
tant role for oxidative phosphorylation andmitochondrial respira-
tion (Leighton et al., 1987; Spolarics et al., 1991). How critical
glycolysis versus respiration is for ECbehavior in vivo is unknown.
One of the rate-limiting checkpoints of the glycolytic flux is
the conversion of fructose-6-phosphate (F6P) to fructose-1,6-
bisphosphate (F1,6P2) by 6-phosphofructo-1-kinase (PFK-1).
Phosphofructokinase-2/fructose-2,6-bisphosphatase (PFKFB)
enzymes synthesize fructose-2,6-bisphosphate (F2,6P2), an
allosteric activator of PFK-1 and the most potent stimulator of
glycolysis (Van Schaftingen et al., 1982). Of all PFKFB iso-
enzymes, PFKFB3 has a much higher kinase activity than
bisphosphatase activity (700-fold), thus favoring the production
of intracellular F2,6P2 levels and controlling its abundance (Yalcin
et al., 2009b). By contrast, the PFKFB4 isoenzyme has a much
weaker kinase activity and has been reported to stimulate or
inhibit glycolysis (Goidts et al., 2012; Ros et al., 2012). Silencing
as well as pharmacological inhibition of PFKFB3 in tumor cells
reduces tumor cell glycolysis and growth (Chesney et al., 1999;
Clem et al., 2008). However, aside from a single study docu-
menting its expression in ECs (Bando et al., 2005), the role of
PFKFB3 in angiogenesis has not been studied. Here, we investi-
gated whether PFKFB3-driven glycolysis regulates vessel
sprouting and whether it affects tip versus stalk cell formation.
RESULTS
Endothelial Cells Are Highly Glycolytic
We first explored whichmetabolic pathway is critical for ECs and
measured the flux of metabolic pathways using radioactive
tracer-labeled substrates in EC monolayers. Arterial, venous,
lymphatic, and microvascular ECs were highly glycolytic (Fig-
ure 1A). Glycolysis was even higher in hemangioma and angio-
sarcoma cells (Figure 1B). Glycolysis levels in ECs were largely
comparable to those in tumor cells but much higher than in
various other healthy cells (Figures 1A and 1B). For most exper-
iments, human umbilical venous endothelial cells (HUVECs) were
used (further denoted as ‘‘ECs’’). Notably, when compared to
glucose oxidation (GO), fatty acid oxidation (FAO), and glutamine
oxidation (QO), glycolytic flux was >200-fold higher (Figure 1C).
Mitochondrial respiration was lower in ECs than in other oxida-
tive cell types (Figure 1D). Calculation of the amount of ATP
showed that glycolysis generated up to 85% of the total cellular
ATP content. Overall, glycolysis is the predominant bioenergetic
pathway for ECs.
PFKFB3 Regulates Glycolysis in ECs
To explore the functional importance of glycolysis in ECs, we
focused on PFKFB3, the most abundant isoenzyme in various
EC subtypes (Figures S1A–S1D available online). PFKFB3652 Cell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc.silencing in EC monolayers with a lentiviral vector encoding a
PFKFB3 small hairpin RNA (shRNA) (PFKFB3KD) lowered PFKFB3
protein levels by 76% (Figure S1E). PFKFB3 knockdown
decreased F2,6P2 levels (Figure S1F); it also reduced glycolytic
flux but by no more than 35% (Figure 1E). Similar effects
were obtained when using PFKFB3-selective RNA interference
(RNAi) oligomers, which lowered PFKFB3 protein levels by 84%
(Figure S1G) and reduced glycolysis by 40% (Figure 1E). PFKFB3
silencing also reduced glycolysis in arterial and microvascular
ECs, as well as in hemangioma and angiosarcoma cells (Fig-
ure 1E). Furthermore, PFKFB3 knockdown decreased F2,6P2
levels in arterial ECs (by 60%) and in hemangioma cells (by 66%).
PFKFB3 Stimulates Vessel Sprouting In Vitro
To study the role of PFKFB3 in vessel formation in vitro, we first
used EC spheroids. PFKFB3KD decreased sprout numbers and
shortened sprout length (Figures 1F–1I). Conversely, overex-
pression of PFKFB3 using a lentiviral vector encoding PFKFB3
(PFKFB3OE) enhanced glycolysis and increased sprout numbers
and length (Figures S1H–S1L). The reduced sprouting of
PFKFB3-silenced ECs was partly due to an impairment of EC
proliferation (Figure 1J) (see below for effects on EC motility).
In contrast, poisoning mitochondrial respiration by using
inhibitors at concentrations that lower oxygen consumption did
not inhibit vessel sprouting (Figures 1K and 1L; Figure S1M).
Conversely, supplements of pyruvate or NADH at concentrations
that increased the oxygen consumption rate failed to affect
vessel sprouting and did not rescue sprouting upon PFKFB3
silencing (Figures 1M and 1N; Figure S1N). Thus, loss- and
gain-of-function studies highlighted that glycolysis, rather than
respiration, regulates vessel sprouting.
PFKFB3 Gene Deletion in ECs Causes Vascular Defects
In Vivo
We then studied the effects of PFKFB3 deficiency on vessel
formation in the postnatal mouse retina. We generated
PFKFB3lox/lox mice and crossed them with VE-cadherin(PAC)-
CreERT2 mice, an EC-specific Cre-driver line (Benedito et al.,
2009), termed PFKFB3vDEC mice. To evaluate the recombination
efficiency, we crossed PFKFB3vDEC mice with mT/mG mice, a
double-fluorescent Cre reporter line that expresses mem-
brane-targeted Tomato (mT) prior to Cre-mediated excision
and GFP (mG) after excision. Treatment of triple-transgenic
pups with tamoxifen at postnatal days 1–4 inactivated PFKFB3
in 50%–85% of ECs, and the PFKFB3-lox allele was correctly
recombined (Figure S2A). EC loss of PFKFB3 diminished the
number of branch points, distal sprouts with filopodia and filopo-
dia (Figures 2A–2H). Distal sprouts in PFKFB3vDEC mice also had
fewer side connections. The radial expansion of the vascular
plexus was reduced in PFKFB3vDEC mice (Figure 2I) to similar
levels as in other models with sprouting defects (Graupera
et al., 2008; Phng et al., 2009). Similar results were obtained
when using Pdgfb-CreERT2 mice, another EC-selective inducible
Cre-driver line (Claxton et al., 2008) (Figures S2A–S2G), termed
PFKFB3pDEC mice. In PFKFB3DEC mice, vessel regression was
increased because collagen IV staining showed that there were
more empty sleeves of basement membrane without ECs (Fig-
ures 2J–2L), whereas EC proliferation was reduced, as revealed
to
ta
l s
pr
ou
t l
en
gt
h 
(m
m) 2.0
1.5
1.0
*
0.5
-oligo
anti A
+ -
- - +
L
30
20
-oligo
anti A
10
*
+ -
- -
+
A
gl
yc
ol
ys
is
(µm
ol 
glu
co
se
/hr
/m
g p
rot
ein
)
1.5
1.0
HUV
HMVHA
0.5
HLy other healthy cells
0
pe
ric
yt
es
ca
rd
io
m
yo
cy
te
s
he
pa
to
cy
te
s
n
e
u
ro
n
s
gl
ia
l c
el
ls
a
di
po
cy
te
s
m
a
cr
o
ph
ag
es
de
nd
rit
ic 
ce
lls
*
*
*
*
*
*
*
*
*
B
gl
yc
ol
ys
is
(µm
ol 
glu
co
se
/hr
/m
g p
rot
ein
)
HUV MCF7 B164TI
U2OSSVR PancO2
HCT
MDA
MS1
CT2A
ECs tumor cells
6
0
4
2
C
6  
ce
lls
)
10
0
FAO GO Glyc QO
5
800
1000
1200
*
*
*
O
CR
 (n
mo
l O
2/m
in
/
m
g 
pr
ot
ei
n)
D
neuronEC HC
4
0
2
CM
*
*
*
E
gl
yc
ol
ys
is 
in
hi
bi
tio
n
(%
 of
 co
ntr
ol) 0
-80
-40
PFKFB3KD
HA HMVMS1SVR
HUV
* *
* * *
sp
ro
ut
s/
sp
he
ro
id
K
H
sp
ro
ut
s/
sp
he
ro
id
50
25
0
ctrl PFKFB3KD
*
*
*
*
*
*
F G
M
sp
ro
ut
s/
sp
he
ro
id
-pyruvate
NADH
+
-- 
-
+
30
20
10
0
PFKFB3KD - + - + - +
N
to
ta
l s
pr
ou
t l
en
gt
h
 
(m
m)
pyruvate
NADH
3
2
1
0
PFKFB3KD - + - + - +
*
* *
*
* *
- 
-
+
- +
-
- +
-- 
-
+- 
-
+
- +
-
I
to
ta
l s
pr
ou
t l
en
gt
h 
(m
m) 4
2
0
ctrl PFKFB3KD
*
sh si
*
pr
ol
ife
ra
tio
n 
(%
 of
 ct
rl)
0
J
ctrl
50
*
PFKFB3KD
100
ECs
ctrl PFKFB3KD
Figure 1. PFKFB3 Regulates Glycolysis and Vessel Sprouting In Vitro
(A) Glycolytic flux in venous (HUV), arterial (HA), lymphatic (HLy), or microvascular (HMV) ECs is higher than in other healthy cells (mean ± SEM; n = 3–5; *p < 0.05
versus HUV).
(B) Glycolysis in primary ECs (HUVEC) is lower than in murine angiosarcoma (SVR) and hemangioma (MS1) cells but comparable to various tumor cell lines (CT2A
mouse glioma, 4T1 mouse breast carcinoma, MDA-MB-231 human breast carcinoma, MCF7 human breast adenocarcinoma, U2OS human osteosarcoma,
B16F10.9 mouse melanoma, PancO2 mouse pancreatic carcinoma, and HCT116 human colon carcinoma) (mean ± SEM; n = 3; *p < 0.05 versus HUV).
(C) Flux analysis of ECs showing that glycolysis (Glyc) is higher than glucose oxidation (GO), fatty acid oxidation (FAO), or glutamine oxidation (QO) (mean ± SEM;
n = 3; *p < 0.001 versus Glyc).
(D) Oxygen consumption rate (OCR) showing lower respiration in ECs than in oxidative cell types (neurons, hepatocytes [HC], and cardiomyocytes [CM]) (mean ±
SEM; n = 11; *p < 0.01).
(E) Reduction in glycolysis in human arterial (HA), human microvascular (HMV), murine hemangioma (MS1), murine angiosarcoma (SVR), and human venous
(HUVECs) ECs upon genetic silencing by using shRNA (PFKFB3KD; sh) or small interfering RNA (si) (mean ± SEM; n = 3; *p < 0.05 versus shCtrl or siCtrl).
(F andG) Representative bright field photographs of EC spheroids showing that PFKFB3-silenced (PFKFB3KD) ECs formed fewer and shorter sprouts. Scale bars,
50 mm.
(H and I) Morphometric analysis revealing that PFKFB3 silencing (PFKFB3KD) reduced the number of sprouts per spheroid (H), as well as total sprout length (I)
(mean ± SEM; n = 30; *p < 0.01).
(J) 3H-thymidine incorporation assay showing that PFKFB3 silencing (PFKFB3KD) reduced proliferation of EC monolayers (mean ± SEM, n = 3, *p < 0.01).
(K and L) Morphometric quantification revealing that inhibition of mitochondrial respiration by oligomycin (oligo) or antimycin A (anti A) did not inhibit spheroid
sprouting (mean ± SEM; n = 30; *p < 0.05 versus untreated spheroids).
(M and N) Morphometric quantification revealing that stimulation of oxygen consumption by supplementation of pyruvate or NADH did not affect spheroid
sprouting or rescue the reduced sprouting upon PFKFB3 blockade (mean ± SEM; n = 30; *p < 0.05 in PFKFB3KD cells versus control cells).
See also Figure S1.by the injection of EdU (Figures 2M–2O). However, EC depletion
of PFKFB3 did not alter the coverage by NG2+ pericytes (Figures
S2H–S2J).
We also analyzed the role of PFKFB3 in vessel formation in the
hindbrain, another model used to study angiogenesis (Fantin
et al., 2013). To assess whether PFKFB3 deficiency affected
this process, we generated high (>90%) chimeric mice by inject-
ing mCherryRed+ wild-type (WT) or PFKFB3/ ES cells in CD-1blastocysts. The vascular area in the ventricular zone was
reduced by 40% in embryonic day 10.5 (E10.5) somite-matched
PFKFB3/ chimeras (Figures 2P–2R), indicating that PFKFB3
regulated vessel sprouting.
PFKFB3 Silencing Impairs Lamellipodia Formation
We then explored whether the vascular defects in mice lacking
endothelial PFKFB3 were also due to EC motility defects, asideCell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc. 653
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Figure 2. PFKFB3 Gene Deletion in ECs Causes Vascular Defects In Vivo
(A and B) Confocal images of isolectin-B4-stained (gray) retinal vessels of postnatal day 5 (P5) pups showing reduced vascular branching in mice with endothelial
PFKFB3 deficiency (PFKFB3vDEC) (B) as compared to wild-type (WT) mice (A). Scale bars, 50 mm.
(C and D) Quantification of the number of branch points at the front (C) or rear (D) in the retinal vasculature of PFKFB3vDEC mice (mean ± SEM; n = 20; *p < 0.03).
(E and F) High-magnification confocal images of retinal vessels at the vascular front in WT (E) or PFKFB3vDEC (F) pups showing fewer filopodia in PFKFB3vDEC
pups. Scale bars, 20 mm.
(G and H) Quantification of distal sprouts with filopodia (G) and the number of filopodia (H) in the retinal vasculature of PFKFB3vDEC mice (mean ± SEM; n = 7–9;
*p < 0.05).
(I) Quantification of retinal vascular outgrowth showing that endothelial PFKFB3 gene deficiency (PFKFB3vDEC) reduces radial expansion (mean ± SEM; n = 8–9;
*p = 0.001).
(J–L) Isolectin-B4 (red) and collagen IV (green) staining of WT (J) and PFKFB3DEC (K) mice showing that PFKFB3DEC ECs had more isolectin-B4 collagenIV+
empty sleeves (arrows). Scale bars, 50 mm. (L) The quantification of the collagenIV+ empty sleeves is shown (mean ± SEM; n = 5–7; *p = 0.002).
(M–O) Staining for EdU (red) and Isolectin-B4 (green), revealing fewer proliferating ECs in PFKFB3DEC (N) than WT (M) mice. Scale bars, 50 mm. (O) The quan-
tification of the proliferating ECs is shown (mean ± SEM; n = 9; *p < 0.05).
(P–R) Confocal images of isolectin-B4-stained (green) hindbrains showing reduced vascularization in the ventricular zone of PFKFB3/ (Q) as compared to WT
(P) chimeras. Scale bars, 50 mm. (R) The quantification of the vascular area is shown (mean ± SEM; n = 4; *p = 0.04).
See also Figure S2.from the aforementioned EC proliferation defects. Because
lamellipodia are critical for ECmotility, we quantified lamellipodia
formation. Time-lapse video imaging of GFP+ ECs revealed that
these cells formed lamellipodial projections over large areas and
had leading-edge projections with a front-to-back distribution,
resulting in cell body displacement (Figures 3A, 3D, and 3G;
Movie S1A). In contrast, PFKFB3-silenced cells formed smaller
lamellipodia and often only formed irregularly bulging protru-
sions (Figures 3B, 3E, and 3G; Movie S1B). Lamellipodia in
PFKFB3-silenced cells were also more transient, and the more
randomly projecting disoriented protrusions were unable to pro-
duce cell displacement (Figures 3C and 3F; Movie S1B). These
cells also formed fewer and shorter filopodia (Figures 3H–3M).
PFKFB3 silencing also impaired EC motility, as it reduced EC
migration and sprout formation in the presence of mitomycin C
(MitoC), which blocks EC proliferation (Figures 3N–3P), and654 Cell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc.decreased the EC migration velocity (Figure 3Q). Moreover,
video imaging of random cell-motility tracks of individual ECs
revealed a greater directional persistence of movement for con-
trol than PFKFB3-silenced cells (Figures 3R and 3S), presumably
because PFKFB3-silenced ECs were unable to form sustained
lamellipodia.
Tip and Stalk Cell Signals Regulate PFKFB3 Levels
We then explored how PFKFB3 regulated vessel sprouting
mechanistically, and therefore first analyzed whether sprouting-
governing signals affected PFKFB3 expression. Indeed, sprout-
ing-inducingsignals (VEGF,FGF2) increasedPFKFB3expression
and glycolysis (Figure 4A), whereas the sprouting-limiting signal
DLL4 (activating Notch) caused opposite effects (Figure 4B).
However, PFKFB3 levels did not alter the genetic tip versus stalk
cell signature of ECs in baseline conditions (Figures 4C and 4D).
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Figure 3. PFKFB3 Blockade Impairs
Lamellipodia Formation
(A–G) Snapshot images of time-lapse video
imaging of GFP+ ECs (Movie S1) are shown to
illustrate the dynamic shape and size changes of
the lamellipodia and cellular protrusions in control
(A and D) and PFKFB3-silenced (B, C, E, and F)
cells. Arrows denote the migration direction.
Lamellipodia in (A), (B), (D), and (E) are the gray
veil-like structures; the nucleus and surrounding
cell organelles are intense white. In control cells,
note the presence of large lamellipodia uniformly
forming over broad sections of the cell’s perimeter
(arrowheads in A andD). In PFKFB3-silenced cells,
note the presence of smaller, more localized
lamellipodia (arrowheads in B and E) or the irreg-
ularly bulging small protrusions (arrowheads in C
and F). (G) The quantification of the lamellipodia
area is shown (mean ± SEM; n = 5 independent
experiments each containing >20 cells analyzed;
*p < 0.05).
(H–M) Micrograph of ECs, stained with CellMask
(gray) and nuclear DAPI (blue), showing filopodia
(arrows) in control cells (H and I), but not in
PFKFB3KD cells (J and K). (I and K) Shown are
higher magnifications of the boxes in (H) and (J),
respectively. (L and M) The quantification of the
number of filopodia (L) and their length (M) is
shown (mean ± SEM; n = 5; *p < 0.05).
(N) Quantification of MitoC-treated ECmigration in
scratch wound assays showing reduced migration
upon silencing of PFKFB3 (PFKFB3KD) (mean ±
SEM; n = 3; *p < 0.05).
(O and P) Morphometric analysis of MitoC-treated
sprouting EC spheroids revealing that the effect of
PFKFB3 silencing (PFKFB3KD) in reducing total
sprout length (O) as well as the number of sprouts
per spheroid (P) is independent of proliferation
(mean ± SEM; n = 30; *p < 0.01).
(Q) Quantification of migration speed showing
reduced migration velocity upon silencing
of PFKFB3 (PFKFB3KD) (mean ± SEM; n = 5;
*p < 0.05).
(R and S) Analysis of random cell-motility tracks by time-lapse imaging of GFP+ ECs. Cell tracks were determined by cell nuclei position and migration origin was
superimposed at the zero-cross point. Compared to the more directional persistence of cell movement in control cells (R), cell movements were more random in
PFKB3-silenced (PFKFB3KD) cells (S).
See also Movie S1.Furthermore, PFKFB3 levels did not alter themolecular signature
of ECs that were genetically or pharmacologically instructed to
the tip or stalk cell phenotype. Indeed, we pretreated ECs with
DAPT to promote a tip cell phenotype, as evidenced by the upre-
gulation of VEGFR2/KDR (tip-cell-enriched gene) by 69% and
downregulation of VEGFR1 (stalk-cell-enriched signal) by 38%.
However, PFKFB3 silencing did not alter the molecular signature
of Notch-silenced cells (Figure 4C). Conversely, we also overex-
pressed the Notch intracellular domain (NICD) to promote a stalk
cell phenotype, as evidenced by the upregulated Notch-target
genes (Figure 4D). In stalk-promoted cells, PFKFB3 overexpres-
sion did not alter gene expression (Figure 4D).
PFKFB3 Levels Influence the Tip Cell Position
We then assessed whether PFKFB3 levels influenced the cell-
autonomous ability of ECs to form tip cells. We therefore gener-ated mosaic spheroids by mixing ECs expressing normal or
silenced levels of PFKFB3 and assessed which ECs were pre-
sent at the tip. PFKFB3 silencing was achieved by lentiviral
transduction of shPFKFB3 and EGFP (PFKFB3KD/GFP). These
cells were mixed in a 1:1 ratio with WT cells expressing
mCherry (WTRED). In control spheroids, generated by mixing
WTRED and EGFP-positive WT cells (WTGFP), comparable
numbers of each genotype were identified at the tip (Figures
4E and 4G). However, when PFKFB3KD/GFP and WTRED cells
were mixed, PFKFB3KD/GFP cells were less frequently present
at the tip (Figures 4F and 4G). Similar results were obtained
when using MitoC-treated ECs, indicating that the reduced
tip cell behavior of PFKFB3KD/GFP cells was not due to impaired
proliferation (Figure S3A). Even when PFKFB3KD/GFP and WTRED
cells were mixed at a 9:1 ratio, fewer PFKFB3KD/GFP cells were
found at the tip (Figure S3B). Conversely, elevated PFKFB3Cell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc. 655
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Figure 4. The Role of PFKFB3 in Tip Cell Formation
(A) Glycolytic flux analysis and western blotting showing that VEGF and FGF2 increased glycolysis (top) and PFKFB3 protein levels (bottom). Ratio represents the
densitometric quantification of PFKFB3 over lamin A/C immunoreactive bands (mean ± SEM; n = 3; *p < 0.05).
(B) Glycolytic flux analysis and western blotting showing that DLL4 reduced glycolysis (top) and PFKFB3 levels (bottom). Ratio represents the densitometric
quantification of PFKFB3 over lamin A/C immunoreactive bands (mean ± SEM; n = 3; *p < 0.05).
(C) Microarray analysis showing that silencing of PFKFB3 (PFKFB3KD) in baseline conditions or after DAPT treatment did not affect the expression of sprouting-
governing genes (n = 3). *p < 0.05 versus control; p was not significant for DAPT versus DAPT + PFKFB3KD. Immunoblotting showed that VEGFR2 protein and
tyrosine phosphorylation levels were not affected (data not shown).
(D) Microarray analysis showing that overexpression of PFKFB3 (PFKFB3OE) did not affect the sprouting-governing gene signature in baseline conditions or after
overexpression of the Notch intracellular domain (NICDOE) (n = 3; *p < 0.05 versus control; &p < 0.05 versus NICDOE).
(E–G) Representative fluorescence photographs of EC spheroids containing a 1:1 mixture of WTRED and WTGFP ECs showing a comparable fraction of WTred and
WTGFP ECs at the tip position (E). In contrast, in spheroids containing a 1:1 mixture of WTRED ECs and ECs with silenced PFKFB3 (PFKFB3KD/GFP), a reduced number
of PFKFB3KD/GFP ECswas present at the tip position (F). (G) The quantification of the fraction of tip cells with the indicated PFKFB3 genotype is shown, revealing the
competitive disadvantage of PFKFB3KD/GFP ECs to reach the tip (n = 30; *p < 0.01). Scale bars, 50 mm.
(H and I) Morphometric quantification of spheroid sprouting showing that Notch1 silenced (NOTCH1KD) ECs form more (H) and longer (I) sprouts but that
hypersprouting was abolished when both Notch and PFKFB3 were silenced (NOTCH1KD/PFKFB3KD) (mean ± SEM; n = 30; *p < 0.05 versus control (gray), &p <
0.0005 versus NOTCH1KD).
(J) Mosaic EC spheroids containing a 1:1 mixture of WTRED and NOTCH1KD/GFP cells showing a larger fraction of NOTCH1KD/GFP cells at the tip (left). However,
compared to WTRED cells, NOTCH1KD/ PFKFB3KD/GFP cells no longer have a tip cell advantage (n = 30; *p < 0.05).
(K and L) EC spheroid sprouting showing that overexpression of the Notch intracellular domain NICD (NICDOE) reduced sprout number (K) and length (L) but that
PFKFB3 (PFKFB3OE) overcomes the impaired sprouting of NICDOE cells (mean ± SEM; n = 30; *p < 0.01 versus ctrl; &p < 0.01 versus PFKFB3OE).
(M–O) Representative fluorescence photographs of mosaic EC spheroids containing a 1:1 mixture of mCherry wild-type (WTRED) and GFP-labeled NICD over-
expressing (NICDOE/GFP) ECs (M) or combined NICD plus PFKFB3-overexpressing (NICDOE/PFKFB3OE/GFP) ECs (N), revealing that NICDOE/PFKFB3OE/GFP cells were
found more frequently at the tip position (N) than NICDOE/GFP cells (M). (O) The quantification of the fraction of tip cells with the indicated genotype is shown,
revealing that PFKFB3 overexpression overcomes the disadvantage of NICDOE/GFP ECs to reach the tip (n = 30; *p < 0.05). Scale bars, 50 mm.
See also Figure S3.
656 Cell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc.
levels improved tip cell formation, though only modestly
(Figure S3C).
PFKFB3 Silencing Impairs Tip Cell Activity
To further document the importance of PFKFB3 during tip
cell competition, we inhibited Notch signaling (which favors
the tip cell phenotype) and examined whether PFKFB3
silencing affected their tip position. Spheroids of ECs in which
Notch signaling was blocked by RNAi-mediated silencing
(NOTCH1KD/GFP) or DAPT treatment formed more numerous and
longer sprouts (Figures 4H and 4I; Figures S3D and S3E), but
PFKFB3 silencing in NOTCH1KD/GFP or DAPT-treated cells
reduced the number and length of the vascular sprouts induced
by Notch inhibition (Figures 4H and 4I; Figures S3D and S3E).
We also used mosaic spheroids containing a 1:1 mixture
of WTRED and NOTCH1KD/GFP cells. NOTCH1KD/GFP cells were
more often detected at the tip (Figure 4J). However, when
PFKFB3 was silenced in NOTCH1KD/GFP cells, the double-
silenced cells were no longer preferentially present at the tip
(Figure 4J). Thus, ECs lacking the genetic determinant of the
stalk phenotype were less able to reside at the tip when their
PFKFB3 levels were reduced. Similar results were obtained
after treatment with MitoC, indicating that the observed find-
ings were not only attributable to differences in proliferation
(Figure S3F).
PFKFB3 Overexpression Improves Tip Cell Behavior
We further analyzed whether elevated PFKFB3 levels could
overrule the stalk-cell-inducing activity of NICD. Vascular
sprouting was impaired in spheroids of ECs overexpressing
NICD (NICDOE) (Figures 4K and 4L). Notably, however, overex-
pression of PFKFB3 in NICDOE cells overcame NICD’s activity
and restored vascular sprouting (Figures 4K and 4L), indicating
that increased PFKFB3-driven glycolysis promoted sprouting,
even when ECs were genetically instructed to adopt a stalk cell
phenotype. Compared to tip cells, stalk cells have fewer and
smaller filopodia and lamellipodia. Formation of lamellipodia
was indeed impaired in NICDOE cells but was restored to near-
normal levels in NICDOE/PFKFB3OE cells (Figure S3G). We also
used mosaic spheroids containing a 1:1 mixture of mCherry+
(WTRED) and GFP+ NICD-overexpressing (NICDOE/GFP) ECs.
Compared to WTred cells, NICDOE/GFP cells were found less
frequently at the tip (Figures 4M and 4O). However, NICDOE/GFP/
PFKFB3OE/GFP cells were present more frequently at the tip (Fig-
ures 4N and 4O). Mitotically inactivated ECs showed similar
responses (Figure S3H).
PFKFB3 Promotes the Tip Cell Position In Vivo
We analyzed the hindbrain vasculature of E10.5 somite-
matched chimeras generated by injecting mCherryRed+ WT
or PFKFB3/ ES cells into CD-1 blastocysts. Hindbrains were
stained for isolectin-B4 and the EC-specific transcription factor
Erg to label ECs, and tip cells were identified as ECs with protru-
sions from where filopodia emerged. Compared to mosaic
mCherryRed+ WT ECs, 33% fewer mCherryRed+ PFKFB3/
ECs were present at the tip (Figures 5A–5E). We also used the
zebrafish model to explore whether endothelial overexpression
of PFKFB3 could overcome the stalk cell phenotype inducedby overexpression of NICD. Using EC-selective fli1-promotor
constructs, we generated transgenic Fli1:EGFPy1 zebrafish over-
expressing mCherryRed and either NICD (NICDOE/RED), PFKFB3
(PFKFB3OE/RED), or both transgenes (NICDOE/PFKFB3OE/RED). All
constructs expressed comparable transgene messenger RNA
levels (data not shown), and the percentage of mosaic inter-
somitic vessels (ISVs) with an mCherryRed+ cell at the tip
was determined. Compared to 50% in control embryos, 60%
of the mosaic ISVs contained an mCherryRed+ tip cell in
PFKFB3OE/RED embryos (Figures 5F–5M and 5V), showing that
PFKFB3 overexpression provides a modest tip cell advantage
in this assay. In NICDOE/RED embryos, only 22% of the ISVs con-
tained an mCherryRed+ tip cell while, notably, up to 67% of
the ISVs contained an mCherryRed+ tip cell in NICDOE/
PFKFB3OE/RED embryos (Figures 5N–5V). Thus, PFKFB3 was
able to overcome NICD’s pro-stalk activity.
Compartmentalization of PFKFB3
The aforementioned results show that PFKFB3 silencing
affected EC motility, a process requiring remodeling of the cyto-
skeleton. Because respiration did not affect sprouting, we
explored a possible link between glycolysis and the actin cyto-
skeleton. To analyze the cellular distribution of mitochondria
in tip cells in vivo, we generated a transgenic MitoEC: mouse
expressing GFP in EC mitochondria. Isolectin-B4 staining of
retinal ECs in vivo showed that mitochondria in tip cells were
present in the perinuclear cytosol and in cytoplasmic protrusions
at the base from where filopodia projected but were excluded
from filopodia (Figures 6A–6C). Staining for the mitochondrial
marker TOMM20 (Figure 6D) and time-lapse video imaging
of mCherry+ ECs in which mitochondria were labeled with
Mito:EGFP (Movie S2) confirmed that mitochondria were
excluded from lamellipodia.
We then analyzed the subcellular localization of glycolytic
enzymes (including PFKFB3) by immunostaining. In spontane-
ously moving ECs, PFKFB3 was detectable in the cell body
and lamellipodia (Figure 6E). Abundant PFKFB3 immunoreac-
tivity was detected in the perinuclear cytosol. When analyzing
PFKFB3 immunoreactive levels in a 300 nm single optical stack
after pseudocolor conversion, PFKFB3-immunoreactive levels
were comparable in lamellipodia and the cell body (Figure 6F).
Quantification of PFKFB3 and F-actin immunoreactivity levels
in single-stack images showed that PFKFB3 was enriched with
F-actin in membrane ruffles at the leading front of lamellipodia,
known to contain a meshwork of polymerized actin filaments
(Figures 6G and 6H). Additional glycolytic enzymes, including
the ATP-generating pyruvate kinase (PK) and phosphoglycerate
kinase (PGK) and others, also colocalized with F-actin in lamelli-
podial ruffles (Figures S4A–S4H). Notably, unlike PKM2, PKM1,
which is involved in ATP production rather than biosynthesis of
macromolecules, also colocalized in lamellipodia (Figures S4I
and S4J). Immunoprecipitation of PFKFB3 followed by immuno-
blotting for b-actin (Figure 6I) or mass spectrometry (Table S1)
confirmed that PFKFB3 interacts with actin. Moreover, PFKFB3
was detectable in both the G- and F-actin cellular fractions
(Figure 6J) but was more abundant in the F-actin fraction of
motile than quiescent contact-inhibited ECs (Figure 6K).
Notably, PFKFB3 was present in the perinuclear cytosol inCell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc. 657
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Figure 5. PFKFB3 Influences the Tip
Position In Vivo
(A–E) Representative fluorescent image of the
hindbrain vasculature in chimericWT (A and B) and
chimeric PFKFB3/ (PFKFB3KO) embryos (C and
D) showing that mCherry+ WTRED ECs contribute
more frequently to the tip position than mCherry+
PFKFB3KO/RED ECs (arrowheads). Staining for Iso-
lectin-B4 is shown is green, mCherry in red, and
Erg in blue. (E) The quantification of the WTRED and
PFKFB3KO/RED tip cells is shown (mean ± SEM;
n = 9–13; p < 0.02). Scale bars, 50 mm.
(F–V) Confocal images of GFP+ vessels in 24 hpf
transgenic mosaic fli1:EGFPy1 embryos express-
ing only mCherryRed (ctrlRED; F–I), coexpressing
mCherry and PFKFB3 (PFKFB3OE/RED; J–M), coex-
pressing mCherry and NICD (NICDOE/RED; N–Q),
or mCherry and NICD plus PFKFB3 (NICDOE/
PFKFB3OE/RED; R–U) showing that overexpression
of PFKFB3 promotes tip cell contribution and can
overcome the NICD-induced tip cell disadvantage.
(G, I, K, M, O, Q, S, U) Shown is a higher magnifi-
cation of the boxes in (F), (H), (J), (L), (N), (P), (R),
and (T). The arrowheads indicate mCherryRed+
ECs that reached the tip position. The dotted lines
indicate the localization of the dorsal aorta and
posterior cardinal vein (bottom) and the dorsal roof
level (top). Scale bars, 50 mm. (V) The fraction
of mosaic ISVs with the indicated tip cell geno-
type in fli1:EGFPy1 zebrafish embryos mosai-
cally overexpressing NICD (NICDOE/RED), PFKFB3
(PFKFB3OE/RED), or both transgenes (NICDOE/
PFKFB3OE/RED) is shown. Compared to controls,
NICDOE/RED ECs were less frequently present at the
tip, while PFKFB3OE/RED or NICDOE/PFKFB3OE/RED
ECs were present more frequently at the tip
position, indicating that PFKFB3 overexpression
overrules the NICD effect (n = 3–4 experiments
with 55 ISVs/experiment; *p < 0.05 versus control;
&p < 0.05 versus NICDOE/RED).contact-inhibited ECs but was relocated into the lamellipodia,
protrusions, and cell-cell bridges in motile ECs (Figures S4K
and S4L).
Furthermore, time-lapse video imaging after transfecting the
ATP biosensor GO-ATeam in spontaneouslymotile ECs revealed
high ATP levels in lamellipodia in leading membrane ruffles (Fig-
ure 6L; Movie S3). Compared to control cells, PFKFB3-silenced
cells had 55% ± 5% fewer lamellipodial ATP hotspots, which
were also 49% ± 9% smaller and contained 57% ± 2% lower
levels of ATP (n = 4–5; p < 0.001) (Figure 6M). However, respira-658 Cell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc.tion blockers did not reduce lamellipodia
ATP levels in the membrane ruffles
(Figure 6N).
Cellular Adaptation to PFKFB3
Silencing
Finally, we explored whether the effects
of PFKFB3 blockade were due to a gen-
eral energy hypometabolism. However,
PFKFB3 silencing did not alter theenergy charge and ATP levels (Figures 7A and 7B), nor did it
induce cell death as analyzed by measuring activated caspase
3 (Figures 7C and 7D) or LDH release (data not shown).
PFKFB3-silenced cells showed no signs of endoplasmic reticu-
lum, energy, or oxidative stress or of autophagy (Figures 7E–
7H). PFKFB3 silencing did also not increase glucose oxidation
and did not induce a switch to fatty acid oxidation or respiration
(Figures 7I and 7J), which would be expected to occur when
cells suffer severe energy deprivation from the blockage of
glycolysis and need to compensate for such cellular energy
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(A–C) High-magnification images of tip cells in the
retina of transgenic P4 MitoEC reporter mice (A),
stained for isolectin-B4 (B and C), revealing that
mitochondria (green; arrows) are present in the
cytosol and large cytosolic protrusions, but not
inside filopodia (arrowheads). (C) Magnification of
the boxed region in (A) and (B) (merger).
(D) High-magnification SIM images of ECs stained
for the mitochondrial marker TOMM20 revealing
that mitochondria are present in the central peri-
nuclear cell body but excluded from the lamelli-
podia (denoted by a white dotted line).
(E and F) SIM imaging of sparsely seeded ECs
immunostained for PFKFB3 revealing positive
signal in the cell body and lamellipodia. (F)
PFKFB3 pseudocolor conversion (from low
[purple] to high [red]) in a 300 nm single optical
stack is shown, revealing comparable levels in
lamellipodia and the cell body. Arrows denote the
migration direction.
(G and H) Quantification of the relative PFKFB3
and F-actin immunoreactive levels in single-stack
images showing that PFKFB3 colocalized with
F-actin inmembrane ruffles.The line in (H) indicates
the distance over which the immunoreactive levels
were quantified (from point ‘‘a’’ to point ‘‘b’’).
(I) Immunoblotting (IB) for b-actin after immuno-
precipitation (IP) of PFKFB3 from EC extracts
using Dynabead-bound anti-PFKFB3 antibody
(aPFKFB3), indicating that PFKFB3 interacts with
actin (lane 3). Lane 1 and 2 show negative con-
trols using naked beads and beads incubated
with irrelevant B16F10.9 control antibody,
respectively.
(J) Immunoblotting for PFKFB3 after ultracentri-
fugation-based separation of G-actin- and
F-actin-enriched fractions showing that PFKFB3
is present in both fractions.
(K) Immunoblotting for PFKFB3 after ultracentri-
fugation-based separation of G-actin- and
F-actin-enriched fractions showing that PFKFB3
is more abundantly associated with F-actin
in proliferating/migrating than contact-inhibited
cells.
(L–N) Snapshot pseudocolored images of time-
lapse videos (Movie S3) of ECs expressing the
ATP-biosensor GO-ATeam showing that mem-
brane ruffles of lamellipodia (arrowheads) contain
high ATP levels in control cells (L), but not in
PFKFB3-silenced cells (PFKFB3KD; M). Lamelli-
podial ATP levels remained unaffected by
treatment with the mitochondrial respiration
blocker oligomycin (N). Color bars indicate the
orange fluorescent protein/GFP emission ratio
(pseudocolor).
SeealsoFigureS4,MoviesS2andS3, andTableS1.stress. PFKFB3-silenced ECs were thus not in energy distress
but rather adapted to a new metabolically balanced state. To
maintain ATP levels, PFKFB3-silenced ECs decreased ATP con-
sumption, as evidencedby a lower ADP/ATP ratio (Figure 7K) and
reduced protein synthesis (Figure 7L) and EC proliferation (see
above), all high-energy-demanding processes. Nonetheless,
PFKFB3 silencing maintained extracellular matrix production(Figure 7M), promoted ECquiescence (Figure 7N), and increased
the oxidative pentose phosphate pathway (oxPPP) (Figure 7O),
thus showing that PFKFB3 knockdown did not cause general
energy hypometabolism but rather suppressed the hypermetab-
olism induced by vessel sprouting. In conditions of stress,
PFKFB3-silenced ECs even increased fatty acid oxidation (Fig-
ure 7P), likely to ensure redox homeostasis (Jeon et al., 2012).Cell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc. 659
AMPKα -pT172
AMPK
ratio (%)
H
ctrl PFKFB3KD
100 ± 30ratio (%)
I
su
bs
tra
te
 o
xid
at
io
n
(re
lat
ive
 to
 co
ntr
ol) 1.5
0
1.0
0.5
glucose palmitate
PFKFB3KD - + - +
ctrl PFKFB3KD
100 ± 16 66 ± 20
LC3
70 ± 9
A
e
n
e
rg
y 
ch
ar
ge 1.0
0
0.5
E
PFKFB3KD
BiP
CHOP
C
M
3 H
-c
ol
la
ge
n 
sy
nt
he
sis
20
0
10
PFKFB3KD - +
L N
O
qu
ie
sc
en
t c
el
ls
(%
 of
 G
0 
ce
lls
)
20
0
PFKFB3KD
40
(re
lat
ive
 to
 co
ntr
ol)
1.0
0
1.5
0.5
*
*
fa
tty
 a
cid
 o
xid
at
io
n 
(re
lat
ive
 to
 co
ntr
ol)
0
1.5
1.0
0.5
-PFKFB3KD + - +
1 0.1
P
glucose (mM)
* *
- +
PFKFB3KD - +
PFKFB3KD - +
*
pr
ot
ei
n 
sy
nt
he
sis 400
0
200
ctrl PFKFB3KD
I
II
β-actin
Tunicamycin
- + -
- - +
p-ATM
total ATM
ratio (%)
ctrl PFKFB3KD
100 ± 0.4 93.5 ± 3.2
TO-PRO 3
caspase-3PFKFB3KD - +
PFKFB3KD - +
AD
P/
AT
P 
ra
tio
*
0
0.04
0.08
K
O
CR
  (n
mo
l O
2
/m
in
/m
g 
pr
ot
ei
n)
0
3
2
1
-PFKFB3KD + - + - +
OCRBAS OCRATP OCRmax
J
B 20
0
10
PFKFB3KD - +
 
AT
P 
le
ve
ls
 
(nm
ol/
10
6  
ce
lls
) D
F G
Figure 7. Adaptation to PFKFB3 Silencing
(A) PFKFB3 silencing did not affect the energy
balance ([ATP] + 1/2 [ADP] / [ATP] + [ADP] +
[AMP]) (mean ± SEM; n = 3; *p < 0.05).
(B) Quantification of ATP content showing
that ATP levels were not affected in PFKFB3-
silenced (PFKFB3KD) cells (mean ± SEM, n = 6;
p = nonsignificant [NS]).
(C and D) Caspase-3 immunostaining (red) in
combination with TO-PRO3 nuclear staining
(blue) showing that PFKFB3 silencing (D) did not
cause apoptosis. Scale bar, 50 mm.
(E) Immunoblotting showing that PFKFB3
silencing did not alter expression levels of
the ER stress markers BiP and CHOP. Tunica-
mycin treatment was used as positive control.
Densitometric quantifications are shown below
the lanes (mean ± SEM; n = 3; p = NS).
(F) Immunoblotting showing that PFKFB3
silencing did not alter the phospho-AMPK/AMPK
ratio. Densitometric quantifications are shown
below the lanes (mean ± SEM; n = 3; p = NS).
(G) Immunoblotting showing that PFKFB3
silencing did not alter the phospho-ATM/ATM
ratio. Densitometric quantifications are shown
below the lanes (mean ± SEM; n = 3; p = NS).
(H) Immunoblotting showing that PFKFB3
silencing did not induce autophagy, assessed
via the LC3-II/LC3-I ratio. Densitometric quanti-
fications are shown below the lanes (mean ±
SEM; n = 3; p = NS).
(I) PFKFB3 silencing did not alter glucose oxida-
tion or fatty acid oxidation (mean ± SEM; n = 3;
p = NS).
(J) PFKFB3 silencing did not alter oxygen
consumption rates (OCR) (mean ± SEM; n = 11;
p = NS).
(K) PFKFB3 silencing reduced the ADP/ATP ratio
(mean ± SEM; n = 3; *p < 0.05).
(L) Protein synthesis (HPG fluorescence intensity)
was reduced in PFKFB3-silenced ECs (mean ±
SEM; n = 3; *p < 0.05).
(M) 3H-proline incorporation assay (103 dpm/hr/
mg protein) showing that PFKFB3 silencing did
not affect collagen synthesis (mean ± SEM; n = 3;
p = NS).
(N) Fluorescence-activated cell sorting analysis of ECs, stained for Hoechst 33342 and EdU, showing a larger fraction of Hoechst2NEduneg cells in G0 phase in
PFKFB3-silenced cells (mean ± SEM, n = 5; *p < 0.001).
(O) PFKFB3 silencing increased the flux through the oxidative pentose phosphate pathway (oxPPP) (mean ± SEM; n = 3; p < 0.05).
(P) PFKFB3 silencing increased fatty acid oxidation under low-glucose (1 mM and 0.1 mM) conditions (mean ± SEM; n = 5; *p < 0.05).DISCUSSION
Endothelial Cells Are Highly Glycolytic
ECs generated up to 85% of their ATP from glycolysis and were
more glycolytic than other healthy cell types. In line with reports
that ECs have a smaller mitochondrial volume fraction (5%) than
oxidative hepatocytes (30%) and that mitochondria in ECs func-
tion as signaling hubs rather than metabolic powerhouses
(Groschner et al., 2012), the flux through glucose, fatty acid,
and glutamine oxidation in ECs was <1% of the glycolytic flux.
The importance of glycolysis for ECs was illustrated by findings
that PFKFB3 silencing reduced vessel sprouting, whereas inhibi-
tion or stimulation of respiration had no effect.660 Cell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc.The dependence of ECs on glycolysis is at first sight surprising
because quiescent ECs are in immediate contact with oxygen in
the blood. Hence, ECs are exposed to sufficient oxygen for
oxidative metabolism, yet they prefer aerobic glycolysis. This is
likely due to various reasons. First, by consuming little oxygen,
they can transfer more oxygen to perivascular cells. Second,
when sprouting into avascular tissues, ECs become exposed
to low levels of oxygen and glucose. Because glucose diffuses
further away from vessels than oxygen (Buchwald, 2011; Gate-
nby and Gillies, 2004), ECs can still rely on anaerobic glycolysis
to form vessels. Third, by maintaining a low oxidative meta-
bolism, ECsminimize the production of reactive oxygen species,
thereby providing protection against their high-oxygen milieu.
Fourth, glycolysis generates ATP more rapidly than oxidative
metabolism, allowing ECs to meet the energy demands for
dynamic rapid changes in motility. Finally, the glycolysis side
pathways are necessary for the biosynthesis of macromolecules
needed for cell mass duplication during cell division.
PFKFB3-Driven Glycolysis Regulates Sprouting
Silencing of PFKFB3 impaired vessel sprouting. These defects
are due to effects on both migrating tip and proliferating stalk
cells. In agreement with findings that cell proliferation requires
glycolysis (Lunt and Vander Heiden, 2011), PFKFB3 inactivation
reduced EC proliferation, implying that the impaired vessel
formation was at least partially due to proliferation defects.
However, PFKFB3 is also important for EC motility. First,
the tip-cell-activating signal VEGF upregulated the levels of
PFKFB3 and glycolysis, whereas the pro-stalk cell signal Notch
had opposite effects. Second, PFKFB3 blockade suppressed
whereas PFKFB3 overexpression stimulated the sprouting of
mitotically inactivated ECs in spheroids. Furthermore, PFKFB3
silencing impaired the motility, lamellipodia/filopodia formation,
and directional migration of EC monolayers, which could
contribute to the impaired vessel outgrowth and branching in
mice with endothelial PFKFB3 deficiency. Third, in mosaic
competition assays in vitro (using mitotically inactivated cells)
and in vivo, ECs with silenced PFKFB3 levels were underrepre-
sented at the tip in baseline and in tip-cell-favoring conditions,
whereas PFKFB3 overexpression promoted the ability of ECs
to form tip cells in baseline conditions in some assays and
promoted tip cell formation of cells overexpressing the pro-stalk
cell signal NICD.
Notably, relative PFKFB3 levels did not alter the relative
expression levels of tip or stalk cell genes, implying that a change
in PFKFB3-driven glycolysis alone sufficed to promote tip cell
activity. It is worth noting that no other signal has so far been re-
ported to overcome NICD’s potent pro-stalk cell activity, raising
the question whether regulation of metabolism is a (perhaps
even ‘‘the’’) key activity of Notch driving stalk cell formation.
Given that tip and stalk cells dynamically interchange positions
(Jakobsson et al., 2010), we speculate that an increased level
of glycolysis does not permanently convert stalk cells into a fixed
tip cell phenotype, but rather that varying levels of glycolysis
dynamically codetermine the fluid tip versus stalk cell pheno-
type. These findings also raise other intriguing questions, such
as for instance whether tip cells can only stay at the tip for as
long as they have sufficient glycolysis. In any case, in parallel
to control by genetic signals, PFKFB3-driven glycolysis also
regulates vessel sprouting.
Compartmentalization of Glycolysis with Actin
Cytoskeleton Remodeling
Filopodia and lamellipodia are essential for tip cells. Contraction
and protrusion of these structures rely on actin cytoskeleton
remodeling and require hydrolysis of large amounts of ATP.
Mitochondria (0.5 to >4.0 mm) are too bulky to fit into thin filopo-
dia and lamellipodia (250 nmwide and high, respectively) but are
mostly present in the perinuclear cytosol, distant from the filopo-
dial tip, which can be up to 10 mm long. Diffusion of ATP from
distant mitochondria in the perinuclear cytosol may thus not beable to support the high and rapidly changing ATP demands
for sustained motor activity at the tip.
Several lines of evidence suggest that glycolytic enzymes are
compartmentalized with F-actin in lamellipodia during vascular
sprouting. First, PFKFB3 and other glycolytic enzymes (including
those generating ATP) were relocated from the perinuclear
cytosol in contact-inhibited ECs into lamellipodia and cell protru-
sions and were enriched in leading membrane ruffles of motile
cells. Interestingly, the pyruvate kinase isoenzyme involved
in ATP production (PKM1) rather than macromolecular bio-
synthesis (PKM2) was present in lamellipodia. Second, ATP
biosensor imaging revealed that lamellipodia contained ‘‘ATP
hotspots,’’ which were reduced when PFKFB3 was silenced,
but not when respiration was blocked. Third, vessel branching
was affected by inhibiting or stimulating glycolysis, but not
by altering respiration. Fourth, PFKFB3 was associated with
F-actin, and this fraction increased during EC migration.
The use of glycolysis to generate energy for motile structures
may seem counterintuitive, as nearly 20-fold less ATP is pro-
duced per unit of glucose by glycolysis than by oxidative
phosphorylation. Several reasons can explain this phenomenon.
First, despite a low intrinsic yield, the yield of ATP generation by
glycolysis can exceed that by glucose oxidation, as long as
glucose is not limiting (DeBerardinis et al., 2008; Vander Heiden
et al., 2009). Second, compartmentalization of glycolysis with
F-actin offers advantages. By creating a ‘‘glycolytic hub,’’ glyco-
lytic enzymes are arranged on a cytomatrix in an assembly line,
where metabolic substrates are passed from one enzyme to
the next. Glycolytic enzymes are activated by actin and help in
assembling actin microfilaments (Real-Hohn et al., 2010). The
enzyme proximity and activation by actin favor maximal rates
of reaction (al-Habori, 1995). Third, rapid extension/retraction
of filopodia and lamellipodia may create an ATP drain for the
cell body. Localizing the ATP supply to compartments where
ATP is consumed can prevent catastrophic ATP depletion.
The link between glycolysis and actin is evolutionarily
conserved, as glycolysis fuels other motile structures such as
flagella of micro-organisms, tentacles of hydra, or cilia of eukary-
otic cells (Baquer et al., 1975; Hereng et al., 2011; Pavlova,
2010). The relevance of this link is underscored by findings that
expression of aldolase, incapacitated to bind actin, paralyzes
fruit flies (Wojtas et al., 1997). PFKFB3 blockade might reduce
angiogenesis also via other mechanisms. For instance, lactate
stimulates angiogenesis via activation of HIF-1a and upregula-
tion of VEGFR2 (Hunt et al., 2007) or via inhibition of the oxygen
sensor PHD2, activating a proangiogenic nuclear factor kB/inter-
leukin-8 program (Ve´gran et al., 2011). The reduced lactate levels
upon PFKFB3 blockade could thus also suppress angiogenesis
via these mechanisms. Also, PFKFB3 has been proposed
to control cell proliferation via glycolysis-independent nuclear
activities (Yalcin et al., 2009a). While perhaps relevant to explain
the effects on EC proliferation, the effects of PFKFB3 on EC
motility are more likely due to compartmentalization of glycolytic
enzymes in the lamellipodia.
General Implications
To date, only genetic signals have been considered to control
vessel sprouting. Our findings add an extra dimension to thisCell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc. 661
traditional concept and imply that metabolism also controls
vessel sprouting. Aside from a genetic signature, tip and stalk
cells thus likely also have a metabolic signature. While our study
documented a role for glycolysis, other metabolic pathways
might also influence vessel formation. In addition, it will be inter-
esting to explore whether targeting PFKFB3 can reduce patho-
logical angiogenesis.
EXPERIMENTAL PROCEDURES
More details can be found in the Extended Experimental Procedures.
Cell Culture and In Vitro Functional Assays
Freshly isolated primary HUVECs were used for metabolic evaluation, prolif-
eration, migration, motility, and spheroid capillary sprouting assays and in
cell-cycle assessments.
RNA and Protein Analysis
RNA expression analysis was done by quantitative RT-PCR. Immunoblotting
of proteins and immunohistochemistry was performed using the antibodies
listed in the Extended Experimental Procedures.
Metabolic Assays
Glycolysis and oxidation of other substrates were determined using radioac-
tively labeled tracers.
Animal Models of Angiogenesis
Tg(fli1:EGFP)y1 zebrafish (Lawson and Weinstein, 2002) were subjected to
Tol2-based transgenic overexpression. Quantification of sprouting of ISVs
was done as explained in the Extended Experimental Procedures. Tamoxifen
was injected intraperitoneally in mouse pups daily from postnatal day 1 to
day 4. Eyes were fixed at postnatal day 5, and retinal flat mounts were
prepared for vascular analysis as described (Phng et al., 2009). Embryonic
hindbrain angiogenesis was assessed in E10.5–E11.5 embryos as described
(Fantin et al., 2013). Experimental animal procedures were approved by the
Institutional Animal Care and Research Advisory Committee of the University
of Leuven.
Statistics
Data represent mean ± SEM of representative experiments unless otherwise
stated. Unless otherwise indicated, statistical significance was calculated by
standard t test (Prism v4.0b), and phenotype severity distributions were
analyzed by the chi-square test. Estimated means, SEMs, and significance
levels were calculated with the general linearmodel univariate statistical model
(SPSS), considering experiment as covariate. p < 0.05 was considered as
statistically significant.
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